Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on September 3, 2019. The registrant is a Delaware corporation with its principal executive offices in San Diego, CA, and its common stock trades on the Nasdaq Capital Market under the symbol TROV.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is an event notification and does not contain financial statements or performance data.
Material Changes
No material financial changes versus a prior comparable period are reported in this document.
Guidance, Outlook, and Management Commentary
Management announced via press release (Exhibit 99.1) that Trovagene, Inc. will present at the H.C. Wainwright 21st Annual Global Investment Conference. The presentation is scheduled for Tuesday, September 10, 2019, at 10:50 a.m. Eastern time. No specific financial guidance, risks, or contingencies are detailed in the body of this filing.
Important Facts for Investors to Verify
- Verify the company name: The filing is for Trovagene, Inc., not Cardiff Oncology, Inc.
- Confirm the presentation details: Date (September 10, 2019), time (10:50 a.m. ET), and event (H.C. Wainwright 21st Annual Global Investment Conference).
- Note that this 8-K contains no financial data; investors should refer to the most recent 10-Q or 10-K for financial metrics.